PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Business Wire•10/11/2026•07:05 ET
0
Key Highlights
- ➤10 mg/kg cohort achieved 46.5% mean splicing correction, highest reported in multiple-dose study
- ➤12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled; results expected in first half of 2027
- ➤10 mg/kg cohort showed improvements across hand function, grip strength, walking, and mobility measures
- ➤$104.8 million cash, equivalents, and securities expected to fund operations into 2028
- ➤FDA partial clinical hold remains open; PepGen is conducting additional mouse studies
Expert Statements
James McArthur, President and Chief Executive Officer of PepGen
“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution”
James McArthur, President and Chief Executive Officer of PepGen
“We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
– Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures –
Get started
Create a free account to read the full story.